

Safety Data Sheet



1. Identification

| | |
|--|--|
| Product Identifier | Testosterone Enanthate |
| Other means of identification | |
| Internal item number | 82393-0601 |
| CAS number | 315-37-7 |
| Synonyms | Testosterone heptanoate |
| Chemical name | Androst-4-en-3-one, 17-[(1-oxoheptyl)oxy]-, (17beta)- |
| Relevant use and restrictions: | For further manufacturing, processing or repacking. |
| Application of substance: | Active pharmaceutical ingredient. |
| Manufacturer/Supplier information | |
| Company name | Pharma Source Direct |
| Address | 8591 Prairie Trail Drive, Ste C-600 Englewood, CO 80112 |
| Website | www.pharmasd.com |
| Emergency phone number | Infotrac: 1-800-535-5053 |

2. Hazard(s) Identification

| | | |
|-----------------------------|---|------------|
| Physical hazards | Not classified | |
| Health hazards | Carcinogenicity | Category 1 |
| | Reproductive toxicity | Category 1 |
| OSHA defined hazards | Not classified | |
| Label elements |  | |

| | |
|--------------------------------|--|
| Signal word | Danger |
| Hazard statement | May cause cancer. May damage fertility or the unborn child. |
| Precautionary statement | |
| Prevention | Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wash thoroughly after handling. Wear protective gloves/protective clothing/eye protection/face protection. |
| Response | If exposed or concerned: Get medical advice/attention. |
| Storage | Store locked up. |
| Disposal | Dispose of contents/container in accordance with local/regional/national/international regulations. |

Safety Data Sheet



Hazards not otherwise classified (HNOC) Not classified.

3. Composition/Information on Ingredients

Substance

| Chemical name | Common name and synonyms | CAS number | % |
|------------------------|--------------------------|------------|-----|
| Testosterone Enanthate | Testosterone heptanoate | 315-37-7 | 100 |

4. First-aid Measures

| | |
|---|--|
| Inhalation | Move to fresh air. Call a physician if symptoms develop or persist. |
| Skin contact | Rinse skin with water/shower. Get medical attention if irritation develops and persists. |
| Eye contact | Rinse with water. Get medical attention if irritation develops and persists. |
| Ingestion | Rinse mouth. If ingestion of a large amount does occur, call a poison control center immediately. |
| Most important symptoms/effects, acute and delayed | Nausea or vomiting. Sore tongue. |
| Indication of immediate medical attention and special treatment needed | Provide general supportive measures and treat symptomatically. |
| General Information | Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention. |

5. Fire-fighting Measures

| | |
|--|--|
| Suitable extinguishing media | Use fire-extinguishing media appropriate for surrounding materials. Water. Foam. Dry chemical or CO ₂ . |
| Unsuitable extinguishing media | None known. |
| Specific hazards arising from the chemical | No unusual fire or explosion hazards noted. |
| Special protective equipment and precautions for firefighters | Wear suitable protective equipment. |
| Fire fighting equipment/instructions | Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing. |

Safety Data Sheet



Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental Release Measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Clean surface thoroughly to remove residual contamination.

Environmental precautions Not available.

7. Handling and Storage

Precautions for safe handling Avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Use of a designated area is recommended for handling of potent materials. Wear personal protective equipment.

Conditions for safe storage, including any incompatibilities Preserve in well-closed, light-resistant containers, and store at 2 to 8°C. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure Controls & Personal Protection

Exposure guidelines No exposure standards allocated.

Biological limit values No biological exposure limits noted for the ingredient(s)

Appropriate engineering controls Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials. Avoid any open handling of this material, particularly for grinding, crushing, weighing, or other dust-generating or aerosol-generating procedures. Use a laboratory fume hood, vented enclosure, glovebox, or other effective containment.

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI

Safety Data Sheet



Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.

Skin protection

Hand protection

Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy. To reduce the risk of contamination of skin and surfaces, wear two pairs of gloves. Remove the outer gloves after handling and cleanup of the material, and remove the inner gloves only after removing other personal protective equipment.

Other

For handling of laboratory scale quantities, a disposable lab coat or isolation gown over street clothes is recommended. Where significant quantities are handled, work clothing and booties may be necessary to prevent take-home contamination.

Respiratory protection

Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).

Thermal hazards

Not available.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

9. Physical and Chemical Properties

| | |
|---|---|
| Appearance | White or creamy white crystalline powder. |
| Physical state | Solid. |
| Form | Powder. |
| Odor | Odorless or faint odor. |
| Odor threshold | Not available. |
| pH | Not available. |
| Melting point/freezing point | 96.8 - 99.5 °F (36 - 37.5 °C) |
| Initial boiling point and boiling range | Not available. |
| Flash point | Not available. |
| Evaporation rate | Not available. |
| Flammability (solid, gas) | Not applicable. |
| Upper/lower flammability or explosive limits | |
| Flammability limit - lower (%) | Not available. |
| Flammability limit - upper (%) | Not available. |
| Explosive limit - lower (%) | Not available. |
| Explosive limit - upper (%) | Not available. |
| Vapor pressure | < 0.0000001 kPa at 25 °C |
| Vapor density | Not available. |

Safety Data Sheet



| | |
|---|---|
| Relative density | Not available. |
| Solubility in water | Insoluble |
| Partition coefficient (n-octanol/water): | Not available. |
| Auto-ignition temperature | Not available. |
| Decomposition temperature | Not available. |
| Viscosity | Not available. |
| Other information | |
| Chemical family | Anabolic steroid. |
| Molecular formula | C ₂₆ H ₄₀ O ₃ |
| Molecular weight | 400.59 |
| Solubility (other) | Very soluble in ether and in dehydrated alcohol |

10. Stability and Reactivity

| | |
|---|--|
| Reactivity | No reactivity hazards known. |
| Chemical stability | Material is stable under normal conditions. |
| Possibility of hazardous reactions | No dangerous reaction known under conditions of normal use. |
| Conditions to avoid | None known. |
| Incompatible materials | None known. |
| Hazardous decomposition products | Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions. |

11. Toxicological Information

Information on likely routes of exposure

| | |
|--|---|
| Inhalation | Due to lack of data the classification is not possible. |
| Skin contact | Due to lack of data the classification is not possible. |
| Eye contact | Due to lack of data the classification is not possible. |
| Ingestion | Based on available data, the classification criteria are not met. |
| Symptoms related to the physical, chemical, and toxicological characteristics | Anabolic steroids: Men and women: Swelling of feet and legs. Weight gain. Nausea. Vomiting. Diarrhea. Acne. Sleep disturbances. Bone or joint pain. Hair loss. Aggressive behavior. Mood swings. Headache. Men: Shrinking of testicles. Urinary difficulties. Breast enlargement or tenderness. Decreased sexual ability. Women: Growth of facial and body hair. Loss of breasts. Swelling of clitoris. Deep voice. Menstrual irregularities. |
| Delayed and immediate effects of exposure | Anabolic steroids: Liver toxicity. Water and sodium retention. Impaired glucose tolerance. Masculinization of females. |
| Cross sensitivity | Persons sensitive to one anabolic steroid or androgen may be sensitive to this material also. |
| Medical conditions aggravated by exposure | Anabolic steroids: Cardiovascular disorders. Kidney or liver impairment. Epilepsy. Migraine. Diabetes mellitus. Hypercalcemia. Sleep disorders. High cholesterol. Breast or prostate cancer (men). |
| Acute toxicity | |

Product

Species

Test Results

Testosterone Enanthate (CAS 315-37-7)

Safety Data Sheet



Oral
LD50

Mouse
Rat

> 3 g/kg
> 1 g/kg

Skin corrosion/irritation

Due to lack of data the classification is not possible.

Serious eye damage/eye irritation

Due to lack of data the classification is not possible.

Respiratory sensitization

Due to lack of data the classification is not possible.

Germ cell mutagenicity

Due to inconclusive data the classification criteria are not met. Testosterone enanthate was positive in the human sperm morphology assay. Testosterone did not induce sperm abnormalities or micronuclei in mice treated in vivo, and it was not mutagenic to bacteria.

Carcinogenicity

May cause cancer. IARC: Group 1; Carcinogenic to humans. Testosterone enanthate produced bladder carcinoma or papilloma at a dose of 12.5 mg per week in a 24-week study in rats. In humans, hepatocellular carcinomas, cholangiocarcinomas, and adenomas were reported after extended treatment of patients with testosterone enanthate. Studies in mice given subcutaneous implants of testosterone showed an increase in cervical-uterine tumors. This effect was not seen in mice and rats given subcutaneous injections of testosterone or in rats given subcutaneous implants. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.

Reproductive toxicity

May damage fertility or the unborn child. Studies in humans have shown that androgens administered during pregnancy cause masculinization of the external genitalia of the female fetus; the degree of masculinization is dose related. In males, absent, low, or reduced sperm or sperm function resulting in possible infertility may occur during high-dose therapy with androgens. In females treated with androgens, the absence of menstruation may result, impairing fertility.

Specific target organ toxicity - single exposure

Due to lack of data the classification is not possible.

Specific target organ toxicity - repeated exposure

Due to lack of data the classification is not possible.

Aspiration hazard

Not classified.

12. Ecological Information

Ecotoxicity

There are no data on the ecotoxicity of this product.

Persistence and degradability

No data is available on the degradability of this product.

Bioaccumulative potential

Not available.

Mobility in soil

Not available.

Other adverse effects

Not available.

13. Disposal Considerations

Safety Data Sheet



| | |
|--|--|
| Disposal instructions | Dispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste. |
| Local disposal regulations | Not available. |
| Hazardous waste code | Not available. |
| Waste from residues / unused products | Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions). |
| Contaminated packaging | Since emptied containers may retain product residue, follow label warnings even after container is emptied. |

14. Transport Information

DOT

Not regulated as a hazardous material by DOT.

IATA

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

No information available.

15. Regulatory Information

Superfund Amendments and Reauthorization Act of 1986 (SARA)

| | |
|--------------------------|---|
| Hazard categories | Immediate Hazard - No Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No |
|--------------------------|---|

| | |
|---|----|
| SARA 302 Extremely hazardous substance | No |
|---|----|

| | |
|--|----|
| SARA 311/312 Hazardous chemical | No |
|--|----|

Other federal regulations

| | |
|---------------------------------------|----------------|
| Safe Drinking Water Act (SDWA) | Not regulated. |
|---------------------------------------|----------------|

| | |
|-------------------------------------|----------------|
| Food and Drug Administration | Not regulated. |
|-------------------------------------|----------------|

| | |
|--|---------------------|
| Drug Enforcement Administration (DEA) (21 CFR 1308.11-15) | Schedule III - 4000 |
|--|---------------------|

US State Regulations

WARNING: This product contains a chemical known to the State of California to cause cancer and birth defects or other reproductive harm.

Safety Data Sheet



International Inventories

| Country(s) or region | Inventory Name | On inventory (yes/no)* |
|-----------------------------|--|------------------------|
| Australia | Australian Inventory of Chemical Substances (AICS) | Yes |
| Canada | Domestic Substances List (DSL) | Yes |
| Canada | Non-Domestic Substances List (NDSL) | No |
| China | Inventory of Existing Chemical Substances in China (IECSC) | No |
| Europe | European Inventory of Existing Commercial Chemical Substances (EINECS) | Yes |
| Europe | European List of Notified Chemical Substances (ELINCS) | No |
| Japan | Inventory of Existing and New Chemical Substances (ENCS) | Yes |
| Korea | Existing Chemicals List (ECL) | No |
| New Zealand | New Zealand Inventory | No |
| Philippines | Philippine Inventory of Chemicals and Chemical Substances (PICCS) | No |
| United States & Puerto Rico | Toxic Substances Control Act (TSCA) Inventory | No |

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other Information

Disclaimer

The information in this SDS has been compiled from sources considered dependable, but has not been independently verified. The company cannot guarantee the accuracy of information herein, and the statements contained should not be considered an official expression. The company will not assume liability for any loss, damage, and/or expense resulting from the use and/or misuse of this product in regards to handling, storage, and/or disposal.

Issue date 18 Mar 2026

Version 1.0

Issued by Pharma Source Direct – Quality Assurance